The deck opens with a title slide, "A Presentation For Investors," dated June 1, 2006. A company overview follows, stating the goal of becoming the standard for improving the efficacy and safety profile of therapies. Phase IV clinical trials are the initial market. The overview also covers the company's founding and headcount. Next come traction and deal figures, then a management and board slide. The product section describes the system, with a technology diagram of cartridges, readers, and informatics, plus a feature list. Market sections size the Phase IV clinical trial and preclinical markets. A value proposition and a pain-points slide come next. A run of chart slides shows drug-level monitoring across chemotherapy courses, with dose adjustment illustrated in each. The closing sections cover drivers for success, the offering, and existing investors. The final slide explains how signal-to-concentration calibration is computed on a server.
Slides worth studying
- Slide 11: Repeats the chart layout of slide 10 with the same axes so the reduced-dose result can be compared directly.
- Slide 12: Uses one chart and a short caption to show how a mid-course correction brings the drug level back to target.
- Slide 6: Places a technology diagram beside the product diagram to show how cartridge, reader and informatics fit together.
Questions about this deck
What market size does the Theranos, Inc. investor deck give for Phase IV clinical trials?
Slide 14 states that the Phase IV Clinical Market = $39 Billion per year. It also lists 600 to 800 ongoing trials per year and an average Theranos Revenue per trial of $50M.
How many slides does the Theranos, Inc. investor presentation have?
The deck has 23 slides. Slide 1 is the title slide, "A Presentation For Investors," dated June 1, 2006, and slide 23 covers the computation of results.
What does the Theranos, Inc. deck say about its offering?
Slide 20 states the objective is a Pre-IPO transaction to facilitate rapid scaling of Theranos production and manufacturing infrastructure. The offering is $30M, with Existing Investors at $15-20M and New Investors at $10-15M.
How is the Theranos, Inc. investor deck structured?
Slide 2 gives the company overview, slide 3 covers traction and deals, and slide 4 covers management and the board. Slides 5 to 8 describe the product, slides 14 and 15 size the Phase IV and preclinical markets, and slides 19 to 21 cover drivers for success, the offering, and existing investors.
Details
- Company: Theranos, Inc.
- Year: 2006
- Type: Pitch deck
- Industry: Healthcare technology
- Pages: 23
More from Theranos
- Theranos presentation, Meeting of the Board of Directors, 7.14.15
- Theranos investor presentation, Partnership meeting 08.06.14
- Theranos, Inc. presentation, December 2010 board meeting
All Theranos decks in the library
Review score: 5 out of 10, Needs substantial work
Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.
The core story of monitoring drug levels and adjusting dose is recoverable, and slides 10 to 12 show it in a clear before-and-after sequence with plain captions. But the deck runs mostly as unvarying bullet lists with tiny type on slides 4 and 21, and the route is muddled: management comes at slide 4 before the product is shown, the value proposition appears twice (slides 9 and 16), and the offering and investor slides sit before a technology slide at the end. Several pages have fit and legibility defects: the caption on slide 22 collides with the footer band, slide 23 text overlaps the footer, the chart on slide 13 has overprinted axis labels and unreadable noise, and slide 6 pairs unlabeled drawings with a stock server photo and no explanation.
Worth keeping: Keep the three-step chemotherapy chart sequence on slides 10 to 12 with its one-sentence takeaway under each chart, and the cartridge, reader, informatics flow on slide 6 as a simple product map.
Most useful repair: Fix the text colliding with the footer band on slides 22 and 23, enlarge or split the dense management and investor lists on slides 4 and 21, and cut the chart on slide 13 down to a readable message.
What would change the score: I would reorder to problem, solution, product, evidence, market, team, offering, and turn the bullet-only slides 3, 9, 16, 17 and 18 into fewer, headline-led pages with a clear point each.
Confidence high. 23 of 23 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-09. Model-assisted review (claude-sonnet-5-5).
Full text of the slides (23 slides)
Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.
Slide 1
Theranos™
A Presentation For Investors
June 1, 2006
Visuals: Top header band: a photographic-style image of rows of binary digits (0s and 1s) in white-blue type over a blue gradient, dissolving from saturated blue #3A6FB8 at the left to near-white at the right and bottom. Logo: the Theranos wordmark in a green (#2E9A6A) serif display face with a darker green outline, a caduceus-like staff over the initial T, and a small TM mark at upper right of the 's'. No charts, tables or other graphics.
Slide 2
Theranos, Inc.
❖ Our immediate goal is to become the standard for improving the efficacy and risk/benefit and safety profile of every therapy.
➢ Initial Market: Phase IV Clinical trials
➢ Product Platform:
➢ System: Cartridges, Readers, Informatics Service
➢ Founded 2003
➢ Menlo Park, CA
➢ 50 Employees
Confidential & Proprietary
2
Visuals: Two decorative illustrations, no charts or photographs. (1) Top-right banner: a horizontal band of blue binary digits (0s and 1s) in mid-blue and light blue, fading to white toward the left and bottom, spanning from about the middle of the top edge to the right edge. (2) Bottom-left banner: a band of blue binary digits fading from strong blue at the left edge to white toward the right, sitting behind the lower bullets. The Theranos green wordmark logo with a trademark symbol sits top-left (see elements).
Slide 3
Theranos
Theranos Today
6 Deals, 5 companies: $6-12M for validation phase
6 Phase IVs: $20-$50M each
$120 - $300M revenue in next 1.5 years
10 companies and 1 government agency: 15 additional deals
$21-52M for validation
$300-$750M for phase IVs
Existing deals: $120M - $1.5Bn in revenue
Improve label, validate efficacy and preempt liabilities
Confidential & Proprietary
3
Visuals: A binary-code (0s and 1s) decorative graphic in blue: a broad band fading from dark blue at top-right to white toward the left across the top edge, and a second band in the bottom-left corner fading from light blue at the bottom-left to white toward the right. No charts, photos, or diagrams. The Theranos wordmark logo in green serif letters with a trademark mark at top-left.
Slide 4
Theranos
Management
Elizabeth Holmes, President and CEO
Left Stanford Chemical and Electrical Engineering to found Theranos, also Genencor, Genome Institute Singapore
Howard Bailey, CFO
Former CFO who took QED and Photon Dynamics public, also CFO Occam, C-Cube, and Controller, Intel
Diane Parks, CCO
Former Senior Vice President, Biotherapeutics and Managed Care, Genentech, also Vice President, Marketing, Aventis
John Howard, Senior VP, Products
Former President, Panasonic Semiconductor, also President, IBM Microelectronics Division
Dr. Ian Gibbons, Senior Director Assay Development
Former Senior Director, Syva, ACLARA, Biotrack, AmCell, First Medical
Tim Kemp, Senior Director Informatics Systems
Former lead systems engineer, IBM, Embedded Systems
Board of Directors:
Donald L. Lucas, Chairman of the Board
46-year veteran of the venture capital business
Elizabeth Holmes
CEO, Theranos
Peter Thomas
Founder and Managing Director, ATA Ventures; General Partner, Institutional Venture Partners
Channing Robertson
Stanford Senior Associate Dean of Engineering
Confidential & Proprietary
4
Visuals: Logo: the green 'Theranos' wordmark with a TM mark at top left, rendered in a serif display face with a caduceus-like staff in the T. Decorative banner top right: a blue gradient field of binary digits (0s and 1s) fading from saturated blue at the right edge to white toward the left, tapering diagonally down-left. Decorative strip bottom left: a faded blue binary-digit band fading from left to right into white, approximately 0 to 62% width and 83% to 100% height. No photographs, charts or tables.
Slide 5
Theranos / What is our system? / www.theranos.com / Confidential & Proprietary / 5
Visuals: Four photographs and one line chart. Photo 1 (top-left): a hand holding a white rectangular plastic card labelled 'Theranos 1.0' with chevron arrows and a red arrow reading 'Place sample here', against a dark wooden surface. Photo 2 (top-middle): a hand holding a translucent white cartridge with a blue glowing light at its left edge and faint channel traces, against a dark background. Photo 3 (top-right): a beige-grey boxed device labelled 'Theranos' with a green LED and red LED on its front face and a sample slot, its open top showing green circuit boards, on a light lavender-grey background. Photo 4 (bottom-left): a hand holding a device with a green circuit board, two white LEDs, stacked transparent acrylic plates and a white ruler above it, on a light grey-white background. Chart (bottom-right): line chart with no title, on a white box with thin grey border. Y-axis 'Bound Label (M)' from 0 to 1.2E-10 with ticks 0, 2E-11, 4E-11, 6E-11, 8E-11, 1E-10, 1.2E-10. X-axis 'Concentration (M)' is logarithmic from 1.00E-12 to 1.00E-08 with a tick each decade. Series 'Competitive' (dark teal-green line): about 7.3E-11 flat at the left, falling gradually through about 4E-11 near 1.00E-10 and reaching about 0 near 1.00E-08. Series 'Two Step' (gold-orange line): about 1.1E-10 at the left, dropping steeply near 5E-11 and reaching about 0 by about 1.00E-09. Legend box at upper right of plot with entries 'Competitive' (green) and 'Two Step' (orange). No highlighted points. Photos are boxed and sharp-edged with no overlay. The top-right and bottom-left binary-code banners are decorative blue gradient graphics, not photos.
Slide 6
Theranos
Technology
Theranos Products
Cartridge
Reader
Informatics
Reagents
Control
Wash 1
Amp
Wash 2
Label 1
Label 2
Push
Test Sites
Motion
Waste Valves
Vacuum Pump
Vacuum Sensor
Mixing
Waste 1
Waste 2
Multiplex Vent Valve
Sample Vent Valve
Separator
Metering
Sample Port
Theranos
Confidential & Proprietary
6
Visuals: Left column of three illustrations, top to bottom: (1) an antibody-style diagram of two red circles with blue Y-shaped antibody pairs on a horizontal baseline with small stalks, about 40 percent of its width in red and blue; (2) a grey microfluidic cartridge schematic on a vertical stand with labelled reagent wells (Reagents, Control, Wash 1, Amp, Wash 2, Label 1, Label 2, Push, Mixing, Separator, Metering, Waste 1, Waste 2), valves (Multiplex Vent Valve, Sample Vent Valve, Vacuum Sensor, Vacuum Pump, Waste Valves), Test Sites and Motion arrow, and Sample Port; (3) an exploded view of four stacked grey-outlined cartridge plates with holes and channels. A curved black bracket connects this column to the frame. Inside the frame: a photograph of a hand holding a white Theranos cartridge card with small text Theranos and blue indicator dots, shown in front of a stack of three orange-red cartridge sheets, cropped as a rectangle with a soft shadow; a black arrow points right to a dark navy and grey rectangular benchtop reader box with a light grey front display strip and round knob; a black arrow points from the reader toward a boxed photograph of a large dark grey server cabinet array in a clean data centre, with a blue-panel module in the middle and rows of server racks on the right, lit by overhead white light with a white floor, framed with a thin light border; three black arrows point down from the photo to three flat-screen monitors on black stands showing purple-and-white software windows with blue and teal panels, placed side by side.
Slide 7
Theranos ABCS™: Ambulatory BioInformatics
Communications System
Pharmacy
Partner
HMO
Theranos Informatics
Home
Telecommunications
Videoconferencing
Effective narrow range therapy through post-prescription
monitoring of the total available patient base.
Confidential & Proprietary
7
Visuals: Diagram with five labelled parts. A green arrow (about 15% of slide width) points left from Partner (grey stacked-block building illustration, upper right) to a brown pill bottle labelled Pharmacy, which has Rx mortar and caduceus icons beneath its label. A vertical green arrow points down from Pharmacy, labelled HMO, to a line-drawn house labelled Home containing a white Theranos device (rounded dome unit with a small red and green indicator) and captions Telecommunications and Videoconferencing beside it. A line-drawn office building with a standing doctor in white coat and stethoscope pointing to a clipboard sits above the house, joined to it by short dashed grey lines. Grey dashed lines radiate from Partner and the office building to a photograph at lower right of a server room: dark grey-brown cabinets with a blue-lit control panel in the centre and rows of grey server racks at right, photographed straight-on, full colour, boxed with a hard rectangular edge, cool white ceiling lighting, no overlay. Labelled Theranos Informatics above the photo.
Slide 8
Product Features
Use: Simultaneous quantitative measurement of drugs and treatment-related biomarkers
Sample Size: 5-10µL of blood
Time: Multiplex assays complete in < 30 minutes
Calibration/Control: On board with each measurement
Operating Principle: Chemiluminescent/Immunoassay
Dynamic Range: Low picogram/mL – high microgram/mL
Accuracy: Results comparable to “gold standards”
Precision: Average total 5-7% Coefficient of Variation or better
Data Reporting: Immediate upload from secured server
Attractiveness: New assays can be developed and implemented within about three months and can be fully developed at ISO 9000 standards within about six months.
Confidential & Proprietary
8
Visuals: Two decorative binary-code illustrations, not photographs: a blue-tinted band across the top right, fading to white toward the left, and a blue-tinted band across the bottom left, fading to white toward the right. Both bands are full-bleed to their corners and show rows of 0 and 1 digits in white and light blue on a medium-blue gradient. The Theranos logo is a green serif wordmark with a small caduceus-like emblem and a trademark TM mark at its upper right. No charts, tables or photographs.
Slide 9
Value Proposition
Increase pharmaceutical sales by improving the label of a compound
Remove black boxes
Safely sell to total available patient base
Introduce existing compounds to market (rather than relying heavily on gene sequencing and new discoveries)
Increase the number of patients enrolling in trials and reduce drop-outs
Increase compliance
Confidential & Proprietary
9
Visuals: Two decorative binary-code (0/1 digit) gradient bands: a blue band fading to white across the top-right corner from roughly the top edge to the title line, and a lighter blue band fading in from the bottom-left corner. The Theranos logo (green serif wordmark with a caduceus-like symbol and TM mark) at top-left. Bullet glyphs are blue arrowhead symbols. No photographs or charts.
Slide 10
Theranos
First course of infusion chemotherapy with
Theranos monitoring
First course of treatment
(Drug level too high)
Parameter
First course dose
First course drug level
Drug level target
Time, hours
Standard dose rate; patient is not eliminating drug rapidly and drug
concentration increases over the target level to a toxic level.
Confidential & Proprietary
10
Visuals: One line chart inside a thin grey bordered box. Title: First course of treatment / (Drug level too high), bold dark grey. Y axis labelled Parameter (rotated vertical, bold), range 0.0 to 3.0 in steps of 0.5, no units printed. X axis labelled Time, hours, range -2.0 to 7.0 in steps of 1.0, no units beyond hours. Series 1, First course dose: navy #2E2E6E line with diamond markers; about 0 at -1.0 and 0.0, about 1.05 at 0.5, about 1.0 at 1.0, 1.5, 2.0, about 1.05 at 2.5, about 1.0 at 3.0, about 0 at 3.5, 4.0, 5.0 and 6.0 (no values printed). Series 2, First course drug level: magenta #E6007E line with square markers; about 0.0 at -1.0 and 0.0, about 0.72 at 0.5, about 1.52 at 1.0, about 2.5 at 1.5, about 2.72 at 2.0 (peak), about 2.42 at 2.5, about 2.22 at 3.0, about 1.52 at 3.5, about 1.22 at 4.0, about 1.02 at 5.0, about 0.92 at 6.0 (no values printed). Series 3, Drug level target: red #FF0000 line with triangle markers at 1.0 for x = 0.5, 1.0, 1.5, 2.0, 2.5, 3.0. Legend box at upper right inside the plot area with three entries: First course dose, First course drug level, Drug level target, each with its marker and line swatch. No highlighted points.
Slide 11
Theranos™ / Second course of infusion chemotherapy with / Theranos monitoring / Second course (Drug dose reduced) / Parameter / 3.0 / 2.5 / 2.0 / 1.5 / 1.0 / 0.5 / 0.0 / -2.0 / -1.0 / 0.0 / 1.0 / 2.0 / 3.0 / 4.0 / 5.0 / 6.0 / 7.0 / Time, hours / Second course dose / Second course drug level / Drug level target / Same patient, second course of therapy; dose is lowered based / on Theranos results >> drug level is at target. / Confidential & Proprietary / 11
Visuals: Line chart titled 'Second course (Drug dose reduced)' inside a thin grey rectangular frame. X axis 'Time, hours' from -2.0 to 7.0 with tick labels at -2.0, -1.0, 0.0, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0. Y axis 'Parameter' from 0.0 to 3.0 in steps of 0.5. No gridlines; plot area has a thin grey border. Series 1 'Second course dose' is a navy line (#2E2A5C) with dark navy diamond markers: about 0 at -1.0 and 0.0, about 0.5 at 0.5 through 3.0 (plateau), about 0 at 3.5, 4.0, 5.0 and 6.0. Series 2 'Second course drug level' is a magenta-pink line (#E0218A) with magenta square markers: about 0 at -1.0 and 0.0, about 0.5 at 0.5, about 0.9 at 1.0, about 1.1 at 1.5, about 0.9 at 2.0, about 0.8 at 2.5, about 1.0 at 3.0, about 0.7 at 3.5, about 0.5 at 4.0, about 0.35 at 5.0, about 0.3 at 6.0. Series 3 'Drug level target' is a thin red line (#E01E1E) with red triangle markers at 1.0 on the y axis for x = 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0. Legend box in the upper right of the plot area with white fill and thin grey border, listing the three series in the order above. No points are highlighted beyond the markers.
Slide 12
Dose Customization
Drug dose adjusted in course
Parameter
First course, drug dose corrected in course
Drug level
Drug level target
Time, hours
Same patient but in the first course rapid (within one hour) feedback from Theranos monitor leads to a decision to stop the infusion. Drug level drops from toxic to target.
Confidential & Proprietary
12
Visuals: Line chart with markers, titled 'Drug dose adjusted in course', inside a thin grey rectangular border. Y axis labelled 'Parameter', range 0.0 to 3.0 with ticks every 0.5 (values about, unitless). X axis labelled 'Time, hours', range -2.0 to 7.0 with ticks every 1.0. Series 1, 'First course, drug dose corrected in course': navy #2E3A6B line with diamond markers; values about 0 at -1.0 to 0.0, rising to about 1.05 near 0.6 and about 1.05 near 1.3, falling to about 0 at 2.0, then about 0 at 2.5, 3.0, 3.5, 4.0, 5.0 and 6.0. Series 2, 'Drug level': magenta #E0007F line with square markers; about 0.0 at -1.0 and 0.0, about 0.7 at 0.5, about 1.5 at 1.0, about 2.5 at 1.5 (peak), about 1.5 at 2.0, about 1.0 at 2.5, about 0.75 at 3.0, about 0.5 at 3.5, about 0.4 at 4.0, about 0.35 at 5.0, about 0.25 at 6.0. Series 3, 'Drug level target': red #FF0000 line with triangle markers, flat at about 1.0 from 0.5 to 3.0 (triangles at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0). Legend box at upper right inside the plot area, white fill with grey border, listing the three series with their marker symbols. No highlighted points beyond the peak. Decorative binary-code banners (blue gradient fading to white) at top right and bottom left, not charts.
Slide 13
Theranos
Real-time PK/PD Monitoring
Scenario: Drug effective; Toxicity observed; Dosage reduced; Toxicity reduced to acceptable level
1.4
1.2
1
0.8
0.6
0.4
0.2
0
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
Parameter Value
Time, days
Drug Dose
Drug Level
Effect marker
Toxicity marker
Tox. Alert Level
Confidential & Proprietary
13
Visuals: Line chart with title 'Scenario: Drug effective; Toxicity observed; Dosage reduced; Toxicity reduced to acceptable level' (bold, two lines, centred above plot). X-axis 'Time, days' from -10.0 to 50.0 with ticks every 10 (labels -10.0, 0.0, 10.0, 20.0, 30.0, 40.0, 50.0). Y-axis 'Parameter Value' from 0 to 1.4 with ticks every 0.2 (0, 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4). Series: Drug Dose (navy #1F1F5C line with diamond markers) about 1 from day 0 to 7, about 0 at days 7 to 8, about 1 from day 8 to 11, then about 0.5 from day 12 to 50. Drug Level (magenta #E0007F line with square markers) peaks about 1.3 near days 2 and 3, about 1.2 near day 10.5, then oscillates between about 0.3 and 0.9 and settles between about 0.3 and 0.6 after day 13. Effect marker (green #00A651 line with triangle markers) starts about 1 at day 0, falls to about 0 near day 7, peaks about 0.25 near day 4.5, then settles between about 0.1 and 0.15 after day 15. Toxicity marker (light blue #00B0F0 line with x markers) peaks about 1.3 at day 10.5, then oscillates between about 0.1 and 0.5 after day 15. Tox. Alert Level is a horizontal red #FF0000 line at 0.4 spanning day 0 to 50. Legend box at upper right of plot lists the five series in order: Drug Dose, Drug Level, Effect marker, Toxicity marker, Tox. Alert Level. No highlighted points.
Slide 14
Theranos™ / Total Available Market: / Phase IV Clinical Trials / Phase IV Clinical Market = $39 Billion per year / Number of ongoing trials per year = 600 to 800 / Average Theranos Revenue per trial = $50M / $7,500 “Information Fee” per patient for every four months / Average: 2,000 to 10,000 patients per trial / Confidential & Proprietary / 14
Visuals: Two decorative binary-code banners (blue digit strips fading to white) and one green Theranos wordmark with a trademark mark. No charts, tables or photographs. The top banner is a wide gradient strip with blue binary digits (0s and 1s) fading to white toward the left and bottom. The bottom-left banner is a smaller strip of pale blue binary digits fading to white toward the top-right. The Theranos wordmark is green serif-style lettering with a dark green outline and a small TM mark at upper right.
Slide 15
Theranos
Total Available Market:
Pharmaceutical preclinical market
Pre-clinical Market = $10 billion per year
$5M annual revenue per research group
133 groups per pharmaceutical company
15 companies of this size
Note: These numbers exclude sales to one of the largest preclinical market segments: academic institutions.
Confidential & Proprietary
15
Visuals: A green serif 'Theranos' wordmark with trademark symbol at top left, on a white ground. A blue gradient binary-code (0s and 1s) banner runs across the top from about 27% to the right edge, fading to white toward the left. A second, smaller blue binary-code banner sits bottom left, fading to white toward the right. No charts, photographs or diagrams.
Slide 16
Theranos
Theranos Value Proposition
Revenue:
Information fee includes use of
Readers
Cartridges
ABCS informatics, patient diary and data integration service
70% margins
Requisite solution for improving labels or preempting liabilities
Cost to pharmaceutical companies is 20-30% less than current costs of equivalent testing through clinicians office
Confidential & Proprietary
16
Visuals: Two decorative illustrations: a blue binary-code (0s and 1s) banner in the top right that tapers and fades to white toward the left and bottom, and a second, fainter binary-code banner in the bottom left that fades to white toward the right. Both are full-width bleed bands with soft gradient edges. The Theranos logo is a green serif wordmark with a caduceus-like staff over the T and a trademark TM mark, at top left. No charts, tables or photographs.
Slide 17
Theranos / ™ / Pains In The Existing Marketplace / Adverse Drug Reactions reduce sales and keep some drugs off the market / Pharmacogenomic tests (diagnostics) do not eliminate adverse drug reactions / And screen some patients who could safely benefit from a drug / No mechanism to measure the effect of environmental factors on drug efficacy / No continuous monitoring to determine the correct dosage / Current testing procedures too expensive or impossible for some drugs / Confidential & Proprietary / 17
Visuals: Top-right banner: a horizontal swoosh of blue binary digits (0s and 1s) fading from saturated blue at the right edge to white toward the left, spanning roughly x 27% to 100% and y 4% to 18%. Bottom-left banner: a pale blue binary-digit band fading from white at the top to light blue at the bottom, spanning roughly x 4% to 63% and y 75% to 95%. Logo: the Theranos wordmark in green serif lettering with a small caduceus-style emblem in the T, with a TM mark at upper right, at top left. No photographs or charts.
Slide 18
Theranos Solution
Monitoring can take place anywhere and can be done by anyone
Monitoring can be as frequent as needed with little increase in cost
Results compare to / beat those obtained by a blood lab
Results are available in minutes
Warning to doctor can be sent within minutes of a test
Effectiveness of dose can be monitored in real time
Drug-drug combinations can be monitored to improve the label
Drugs can be prescribed with monitoring devices to prevent ADRs
Instant analysis and availability of related data improve speed and effectiveness of trials
Consumer WWW increases value of therapy: Informs patients, drives compliance and increases patient adherence to given drug
Confidential & Proprietary
18
Visuals: Decorative background bands only, no photographs or charts. Top-right band: a horizontal strip of blue binary digits (0s and 1s) fading from saturated medium blue #3F7FC4 at its right edge to white at its left edge, tapering diagonally, spanning roughly the top 19% of the slide. Bottom-left band: a faded light blue binary-digit strip fading to white toward the right, spanning about y 81% to 95% and x 4% to 62%, with a soft gradient edge. Logo: Theranos wordmark in green #3A9A5B serif-style letters with a small caduceus-like emblem in the T, and a small TM mark at upper right of the wordmark. Bullet glyphs are small blue arrowhead symbols (Wingdings-style) in #1F6FA8.
Slide 19
Theranos / Drivers for Success / First mover advantage / Combination of several different technologies makes reproducing the solution difficult / Innovation Pipeline: Next generation systems / Strong Customer Base / Speed to Market and Focus on Quality / Patents / Management and Culture / Confidential & Proprietary / 19
Visuals: Two decorative illustrations, both made of blue binary digits (0s and 1s) on a fading white field. The top-right illustration is a horizontal band of blue binary text, darkest blue at its right edge and fading to white toward the left and bottom, with a tapered lower edge. The bottom-left illustration is a band of pale blue binary text that fades to white toward the top and right. No photographs, charts, tables, or diagrams. The only logo is the green Theranos wordmark with a trademark mark at its top right.
Slide 20
Theranos™ / Offering / Objective: Pre-IPO transaction to facilitate rapid scaling of Theranos production and manufacturing infrastructure and add to Theranos business development and sales force. / CFP / Offering: $30M / Existing Investors: $15-20M / New Investors: $10-15M / Confidential & Proprietary / 20
Visuals: Decorative graphic: a blue gradient band of binary digits (1s and 0s) fading to white, running from the top-right corner leftward and tapering to the left, and a second smaller band of binary digits at the bottom-left fading to white toward the right. No photographs, charts, or tables. Logo: green 'Theranos' wordmark with a stylised caduceus-like figure replacing the 'T', outlined in lighter green, with a small TM mark at upper right.
Slide 21
Theranos / Existing Investors / Lead investor profiles: / Series A / Chang, Esoom Taipei: Multi-billion dollar distribution group; leading distributors of high / technology devices in Asia with headquarters in China and in Taiwan. / Continental Properties Company: Fund lead by John Schweitzer and Stephen Feinberg, / director of MD Anderson, leading center in innovative cancer treatment, cutting-edge / research and clinical trials. / Draper Fisher Jurvetson: Draper Fisher Jurvetson is a global network of affiliated venture / funds with over $3 billion in capital commitments and offices in the major technology centers / around the world. / Jupiter Partners: Fund lead by John Bryan, limited partner in numerous venture capital and / private equity funds and leading investor in companies ranging from Amgen to Hewlett / Packard. / Palmieri Trust: Fund lead by Victor Palmieri, business takeover financier; director of / numerous high growth companies including Phillips Petroleum, the Pennsylvania Company, / Arvida Corporation, Outlet Communications, the William Carter Company, Broadcasting / Partners, and Mullin Consulting and a Trustee of The Rockefeller Foundation. / Series B / Donald L Lucas fund: Premier Silicon Valley venture capital veteran (note biography in board / profile document) / ATA Ventures (Early Stage Venture Capital) / Larry Ellison, Tako Ventures / Dixson Doll (Doll Capital Management) / Ray Bingham, BJ Cassin, other private equity investors / Confidential & Proprietary / 21
Visuals: Logo: green Theranos wordmark in a serif-style face with a dark outline and a registered trademark mark (TM) at upper right of the word, at top left. Decorative graphic: a band of blue binary digits (0s and 1s) across the top right, running from about 27% to 95% of slide width and fading from saturated blue at the top-right edge to white toward the left. A second band of blue binary digits lies bottom left, from about 4.5% to 62% of width and 84% to 100% of height, fading to white toward its right end and behind the last bullet lines. No photographs, charts or tables.
Slide 22
Technology: Theranos System versus Today's Lab
Theranos™
Normalized response
1 / 0.9 / 0.8 / 0.7 / 0.6 / 0.5 / 0.4 / 0.3 / 0.2 / 0.1 / 0
1 / 10 / 100 / 1000 / 10000 / 100000
Concentration of TxB2 (pg/mL)
Theranos Assay
Conventional Assay
Measured (pg/mL)
Actual (pg/mL, 4x)
5N+1 / 5N-1 / 5A-1 / 5F-2 / 4N+2 / 4A-2 / 4N-3 / 4F-3
Calculated Concentration pg/mL (log scale)
Spiked Concentration pg/mL (log scale)
All data / Subject 4 / Subject 5 / Linear (All data)
Signal (RLU)
Concentration of TxB2 (pg/mL)
Sample 4 / Sample 5 / Calibration
Luminometer correlation
Upper end of linear range
y = 0.9334x + 0.3992 / R² = 0.9915 / R = 0.995
Projected signal / modulation of / Theranos Chip-/ based assay in / 5 uL volume
Log Theranos Response (Counts/sec)
Log MD response (counts/sec)
Luminometer correlation / Linear (Luminometer correlation)
On chip Chemiluminescence enables greater sensitivity than the clinical / lab
Confidential & Proprietary
22
Visuals: Five charts. (1) Line and scatter chart, Normalized response (0 to 1, linear) versus Concentration of TxB2 (pg/mL) (1 to 100000, log scale); Theranos Assay series is blue diamond markers with a blue fitted curve, Conventional Assay series is red square markers with an orange fitted curve; no values printed, about 1.0 at 1 pg/mL falling to about 0.05 at 100000 pg/mL; legend in a box inside the plot at lower left; points at about 1000 pg/mL cross near 0.6; boxed by a thin grey frame. (2) Log-log scatter, Measured (pg/mL) axis 0.1 to 100000 versus Actual (pg/mL, 4x) axis 0.1 to 100000; eight series of small coloured markers (5N+1 black diamond, 5N-1 magenta square, 5A-1 yellow triangle, 5F-2 cyan x, 4N+2 purple x, 4A-2 dark red circle, 4N-3 teal plus, 4F-3 blue plus) clustered on a thin black diagonal line; legend box at right. (3) Scatter, Calculated Concentration pg/mL (log scale) 1.0 to 5.0 versus Spiked Concentration pg/mL (log scale) 1.0 to 5.0; All data as small black dots, Subject 4 as magenta open squares, Subject 5 as dark magenta open triangles, a black linear trend line; legend box at lower right of plot; framed by a thin purple-grey box. (4) Scatter with curve, Signal (RLU) 0 to 50000 versus Concentration of TxB2 (pg/mL) 10 to 100000 (log scale); Sample 4 dark teal squares, Sample 5 orange-red diamonds, dark grey Calibration curve that is flat near 40000 at low concentration, falls steeply between 100 and 3000, then levels near 5000 at 100000; legend box at upper right; framed by a thin purple-grey box. (5) Scatter with linear fit, Log Theranos Response (Counts/sec) 2.0E+00 to 7.0E+00 versus Log MD response (counts/sec) 2.0E+00 to 7.0E+00; navy diamond markers rising from about 2.5 to 6.5 with a dark navy linear fit line; horizontal red line at 6.5E+00 labelled Upper end of linear range; text y = 0.9334x + 0.3992, R² = 0.9915, R = 0.995; red vertical double-headed arrow at right with the annotation Projected signal modulation of Theranos Chip-based assay in 5 uL volume; legend box at bottom with Luminometer correlation and Linear (Luminometer correlation). Also a Theranos logo, a blue binary-code banner (repeated 0 and 1 digits) at the top right and bottom left.
Slide 23
Theranos
Computation of results
12000
10000
8000
6000
4000
2000
0
Signal
Measured signal (sent to Theranos server)
Dose-response relationship (Factory calibration)
Derived concentration
1
10
100
1000
10000
100000
Progesterone concentration in diluted sample (pg/ml)
Concentration in sample = Signal >> Derived conc. * Dilution factor (fixed)
Computation performed at Theranos server
Chemistry is calibrated through Theranos server by comparing results on cartridge to known results for calibration wells in database so as to preempt use of environmentally deteriorated cartridges
Confidential & Proprietary
23
Visuals: Line chart with no chart title. Y axis: linear, 'Signal' (no units), range 0 to 12000, major ticks every 2000. X axis: logarithmic, 'Progesterone concentration in diluted sample (pg/ml)', range 1 to 100000, ticks at 1, 10, 100, 1000, 10000, 100000. One series, a dark grey (#333333) curve about 1.5 px wide with no markers: about 10900 at x=1, about 10600 at x=10, about 9600 near x=50, then falling steeply through about 6000 near x=250 and about 2000 near x=2000, flattening to about 900 from x=50000 to x=100000. No printed data values; all values are estimates. No legend. Annotations: a red horizontal arrow at signal about 9300 running from the y-axis (x=1) to the curve (x=about 60), with a red vertical arrow dropping from the curve at x=about 65 to the x-axis at 0; the red arrowheads mark the measured point on the curve and the derived concentration on the axis. Dark grey thin arrows point from the labels 'Measured signal (sent to Theranos server)' to the red start point, from 'Dose-response relationship (Factory calibration)' to the curve at about x=200, and from 'Derived concentration' to the red arrow tip on the axis. Chart panel is boxed by a thin grey (#999999) 1 px border with a white fill.
Download this deck
The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.
Building a pitch deck of your own? The SlideDeck Co Startup Deck is a slide library with a worked investor pitch and financial model.






